Novo Nordisk A/S NVO:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 05/10/24 EDT

128.42UNCH (UNCH)

Volume

53,640

128.42

-0.24 (-0.19%)

Volume

3,004,157

52 week range

75.56 - 138.28

Open129.09
Day High130.27
Day Low128.33
Prev Close128.66
52 Week High138.28
52 Week High Date03/07/24
52 Week Low75.56
52 Week Low Date07/11/23

Key Stats

Market Cap579.174B
Shares Out4.51B
10 Day Average Volume4.71M
Dividend1.37
Dividend Yield1.06%
Beta0.41
YTD % Change24.14

KEY STATS

Open129.09
Day High130.27
Day Low128.33
Prev Close128.66
52 Week High138.28
52 Week High Date03/07/24
52 Week Low75.56
52 Week Low Date07/11/23
Market Cap579.174B
Shares Out4.51B
10 Day Average Volume4.71M
Dividend1.37
Dividend Yield1.06%
Beta0.41
YTD % Change24.14

RATIOS/PROFITABILITY

EPS (TTM)2.88
P/E (TTM)44.57
Fwd P/E (NTM)0.82
EBITDA (TTM)17.043B
ROE (TTM)99.87%
Revenue (TTM)35.307B
Gross Margin (TTM)84.65%
Net Margin (TTM)36.55%
Debt To Equity (MRQ)27.22%

EVENTS

Earnings Date08/07/2024(est)
Ex Div Date03/22/2024
Div Amount0.9293
Split Date-
Split Factor-

Latest On Novo Nordisk A/S

Rethinking obesity & weight loss: How taking Ozempic changed author Johann Hari's lifeMay 9, 2024CNBC.com
Healthy Returns: Eli Lilly, Novo Nordisk are boosting weight loss drug supply May 7, 2024CNBC.com
New rivals could threaten Novo Nordisk, Eli Lilly's weight loss drug dominance May 7, 2024CNBC.com
Amgen stock soars on weight loss drug progress as Novo Nordisk, Eli Lilly slideMay 3, 2024CNBC.com
Wegovy maker Novo Nordisk extends losses following first-quarter resultsMay 3, 2024CNBC.com

Content From Our Affiliates

Flagship Pioneering, Metaphore announce research collab with Novo NordiskMay 9, 2024TipRanks
Drugmakers work to make treatments to maintain weight loss, WSJ reportsMay 8, 2024TipRanks
Novo Nordisk Executes Major Share BuybackMay 6, 2024TipRanks
Novo Nordisk Executives Trade Company SharesMay 6, 2024TipRanks
Amgen price target raised to $325 from $315 at BofAMay 3, 2024TipRanks

Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral...

Henrik Poulsen

Vice Chairman of the Board

Helge Lund

Independent Chairman of the Board

Lars Fruergaard Joergensen

President, Chief Executive Officer

Maziar Doustdar

Executive Vice President - International Operations

Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

Douglas Langa

Executive Vice President, North America Operations

Address

Novo Alle 1

Bagsvaerd

2880

Denmark

https://www.novonordisk.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
JNJ Johnson & Johnson	149.91	+0.06	+0.04%
CAH Cardinal Health Inc	99.53	+1.47	+1.50%
RDY Dr Reddy's Laboratories Ltd	69.17	-0.29	-0.42%
MRK Merck & Co Inc	130.06	-0.17	-0.13%
ABBV AbbVie Inc	160.75	+0.35	+0.22%